Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Assets (2016 - 2025)

Protalix BioTherapeutics has reported Current Assets over the past 16 years, most recently at $66.7 million for Q4 2025.

  • Quarterly results put Current Assets at $66.7 million for Q4 2025, up 10.98% from a year ago — trailing twelve months through Dec 2025 was $66.7 million (up 10.98% YoY), and the annual figure for FY2025 was $66.7 million, up 10.98%.
  • Current Assets for Q4 2025 was $66.7 million at Protalix BioTherapeutics, roughly flat from $66.5 million in the prior quarter.
  • Over the last five years, Current Assets for PLX hit a ceiling of $95.9 million in Q2 2021 and a floor of $44.9 million in Q4 2022.
  • Median Current Assets over the past 5 years was $66.0 million (2025), compared with a mean of $65.4 million.
  • Biggest five-year swings in Current Assets: surged 76.95% in 2021 and later plummeted 48.19% in 2022.
  • Protalix BioTherapeutics' Current Assets stood at $61.7 million in 2021, then decreased by 27.22% to $44.9 million in 2022, then skyrocketed by 55.82% to $69.9 million in 2023, then dropped by 14.09% to $60.1 million in 2024, then rose by 10.98% to $66.7 million in 2025.
  • The last three reported values for Current Assets were $66.7 million (Q4 2025), $66.5 million (Q3 2025), and $65.5 million (Q2 2025) per Business Quant data.